These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 11173047)

  • 1. Cyclooxygenase inhibition and thrombogenicity.
    Catella-Lawson F; Crofford LJ
    Am J Med; 2001 Feb; 110 Suppl 3A():28S-32S. PubMed ID: 11173047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    Patrono C; Patrignani P; García Rodríguez LA
    J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
    Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
    Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 inhibitors: a review.
    Houston AM; Teach SJ
    Pediatr Emerg Care; 2004 Jun; 20(6):396-9; quiz 400-2. PubMed ID: 15179150
    [No Abstract]   [Full Text] [Related]  

  • 6. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
    FitzGerald GA
    Am J Cardiol; 2002 Mar; 89(6A):26D-32D. PubMed ID: 11909558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase inhibition in patients with coronary artery disease.
    Frishman WH
    J Am Coll Cardiol; 2004 Feb; 43(4):532-3. PubMed ID: 14975459
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
    Pairet M; Engelhardt G
    Fundam Clin Pharmacol; 1996; 10(1):1-17. PubMed ID: 8900495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
    Szczeklik A; Sanak M
    Clin Exp Allergy; 2002 Mar; 32(3):339-42. PubMed ID: 11940059
    [No Abstract]   [Full Text] [Related]  

  • 14. [COX-2 expression in gastric cancers].
    Sakamoto C
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():598-603. PubMed ID: 11424449
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular events and COX-2 inhibitors.
    McGeer PL; McGeer EG; Yasojima K
    JAMA; 2001 Dec; 286(22):2810; author reply 2811-2. PubMed ID: 11735747
    [No Abstract]   [Full Text] [Related]  

  • 16. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?
    Bing RJ; Lomnicka M
    J Am Coll Cardiol; 2002 Feb; 39(3):521-2. PubMed ID: 11823092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction. The role of COX-2-specific inhibitors in clinical practice.
    Lipsky PE
    Am J Med; 2001 Feb; 110 Suppl 3A():1S-2S. PubMed ID: 11173042
    [No Abstract]   [Full Text] [Related]  

  • 18. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2: separating myth from reality.
    McKenna F
    Scand J Rheumatol Suppl; 1999; 109():19-29. PubMed ID: 10422543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and clinical action of COX-2 selective NSAIDs.
    Bovill JG
    Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.